appliedclinicaltrialsonline2d
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a ...
appliedclinicaltrialsonline3d
2025 Trends: Leveraging Data Standards
In this video interview, Kimberly Tableman, founder & CEO, ESPERO, highlights how data standards are empowering the use of ...
appliedclinicaltrialsonline3d
FDA Approves Eli Lilly’s Omvoh for Crohn’s Disease Based on Phase III VIVID-1 Trial Outcomes
In the pivotal trial, patients treated with Omvoh experienced significant improvements in clinical remission and endoscopic ...
appliedclinicaltrialsonline3d
Long-Term KATHERINE Trial Analysis Shows Kadcyla Significantly Improves Survival in HER2-Positive Early Breast Cancer
An updated long-term analysis of the Phase III KATHERINE trial confirms that adjuvant treatment with Kadcyla (trastuzumab ...
appliedclinicaltrialsonline4d
2025 Trends: Advancements in Data Interoperability
In this video interview, Kimberly Tableman, founder & CEO, ESPERO, talks protocol submission formats and how data interoperability can support artificial intelligence.